July 08, 2022
Back Page
42
7
Issue represents a potential threat in fighting future pandemics.
July 08, 2022
Features
42
7
Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
July 08, 2022
Features
42
7
With heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.
July 08, 2022
Features
42
7
A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.
July 08, 2022
Features
42
7
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.
July 08, 2022
Executive Profile
42
7
Dealing with discrimination and bias throughout her career, Otsuka Pharmaceutical’s Christine Sakdalan has forged a strong leadership path built around a two-pronged mission—finding true meaning in the patient journey through market research and data analytics, and mentoring and supporting the development of today’s aspiring professionals.
July 08, 2022
Finance
42
7
A summary of key takeaways from EY’s new Beyond Borders report.
July 08, 2022
Managed Markets
42
7
Reversing non-formulary status will usually require new data.
July 08, 2022
DE&I
42
7
For industries like pharma, company voices are vital to building trust.
July 08, 2022
APAC
42
7
Continent has shed its ‘emerging’ status on world biopharma stage.
July 08, 2022
Europe Report
42
7
Legislative-reform alliance makes for strange bedfellows.
July 07, 2022
Issue PDF
42
7
Click the title above for a link to open the Pharmaceutical Executive July 2022 issue in an interactive PDF format.
June 15, 2022
Features
42
7
Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
June 06, 2022
Washington Report
42
7
Agency again pursuing manufacturer rating system.